Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $0 | $3 | $0 |
| Gross Profit | -$1 | $0 | -$3 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5 | $0 | $1 | $1 |
| SG&A Expenses | $5 | $0 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $6 | $0 | $3 | $3 |
| Operating Income | -$7 | -$0 | $4 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$2 |
| Pre-Tax Income | -$7 | -$0 | -$4 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$0 | -$4 | -$5 |
| % Margin | – | – | – | – |
| EPS | -2.13 | -2.37 | -1.62 | -2.64 |
| % Growth | 10.1% | -46.3% | 38.6% | – |
| EPS Diluted | -2.13 | -2.37 | -1.62 | -2.64 |
| Weighted Avg Shares Out | 3 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $3 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$5 | -$0 | -$5 | -$3 |
| % Margin | – | – | – | – |